Q. No.Match List I with List II:
Choose the correct answer from the options given below:
1. A-III, B-I, C-II, D-IV
2. A-III, B-IV, C-I, D-II
3. A-II, B-IV, C-I, D-III
4. A-II, B-I, C-IV, D-III
| List I | List II | ||
| A. | \(\alpha-1\) antitrypsin | I. | Cotton bollworm |
| B. | Cry IAb | II. | ADA deficiency |
| C. | Cry IAc | III. | Emphysema |
| D. | Enzyme replacement therapy | IV. | Corn borer |
1. A-III, B-I, C-II, D-IV
2. A-III, B-IV, C-I, D-II
3. A-II, B-IV, C-I, D-III
4. A-II, B-I, C-IV, D-III
Subtopic: Intro to Agri Applications | Bt Crops | Gene Therapy |
83%
From NCERT
NEET - 2024
To view explanation, please take trial in the course.
NEET 2026 - Target Batch - Vital
Hints
To view explanation, please take trial in the course.
NEET 2026 - Target Batch - Vital
Match List - I with List - II
Choose the correct answer from the options given below:
| List-I | List-II | ||
| (A) | Gene therapy | (I) | Separation of DNA fragments |
| (B) | RNA interference | (II) | Diagnostic test for AIDS |
| (C) | ELISA | (III) | Cellular defense |
| (D) | Gel Electrophoresis | (IV) | Allows correction of a gene defect |
Choose the correct answer from the options given below:
| Options: | (A) | (B) | (C) | (D) |
| 1. | IV | I | II | III |
| 2. | IV | II | III | I |
| 3. | IV | III | II | I |
| 4. | IV | III | I | II |
Subtopic: Interference RNA Tech | Med Applications & Humulin | Gene Therapy | Molecular Diagnosis |
91%
From NCERT
NEET - 2023
To view explanation, please take trial in the course.
NEET 2026 - Target Batch - Vital
Hints
To view explanation, please take trial in the course.
NEET 2026 - Target Batch - Vital
The genetic defect-Adenosine Deaminase (ADA) deficiency may be cured permanently by:
| 1. | periodic infusion of genetically engineered lymphocytes having functional ADA cDNA |
| 2. | administering adenosine deaminase activators |
| 3. | introducing bone marrow cells producing ADA into cells at early embryonic stages |
| 4. | invitro cell culture therapy |
Subtopic: Gene Therapy |
89%
From NCERT
AIPMT - 2009
To view explanation, please take trial in the course.
NEET 2026 - Target Batch - Vital
Hints
To view explanation, please take trial in the course.
NEET 2026 - Target Batch - Vital
The site of production of ADA in the body is:
1. erythrocytes
2. lymphocytes
3. blood plasma
4. osteocytes
Subtopic: Gene Therapy |
87%
From NCERT
To view explanation, please take trial in the course.
NEET 2026 - Target Batch - Vital
Hints
To view explanation, please take trial in the course.
NEET 2026 - Target Batch - Vital
The first clinical gene therapy was done for the treatment of
| 1. | AIDS |
| 2. | Cancer |
| 3. | Cystic fibrosis |
| 4. | SCID (Severe Combined Immuno Deficiency resulting from the deficiency of ADA |
Subtopic: Gene Therapy |
95%
From NCERT
To view explanation, please take trial in the course.
NEET 2026 - Target Batch - Vital
Hints
To view explanation, please take trial in the course.
NEET 2026 - Target Batch - Vital
ADA is an enzyme which is deficient in a genetic disorder SCID. What is the full form of ADA?
1. Adenosine deoxyaminase
2. Adenosine deaminase
3. Aspartate deaminase
4. Arginine deaminase
Subtopic: Gene Therapy |
95%
From NCERT
To view explanation, please take trial in the course.
NEET 2026 - Target Batch - Vital
Hints
To view explanation, please take trial in the course.
NEET 2026 - Target Batch - Vital
In gene therapy of Adenosine Deaminase (ADA) deficiency, the patient requires periodic infusion of genetically engineered lymphocytes because:
| 1. | Genetically engineered lymphocytes are not immortal cells. |
| 2. | Retroviral vector is introduced into these lymphocytes. |
| 3. | Gene isolated from marrow cells producing ADA is introduced into cells at embryonic stages |
| 4. | Lymphocytes from patient's blood are grown in culture, outside the body. |
Subtopic: Gene Therapy |
75%
From NCERT
NEET - 2022
To view explanation, please take trial in the course.
NEET 2026 - Target Batch - Vital
Hints
To view explanation, please take trial in the course.
NEET 2026 - Target Batch - Vital
When gene targeting involving gene amplification is attempted in an individual's tissue to treat disease, it is known as:
| 1. | Molecular diagnosis | 2. | Safety testing |
| 3. | Biopiracy | 4. | Gene therapy |
Subtopic: Gene Therapy |
70%
From NCERT
NEET - 2021
To view explanation, please take trial in the course.
NEET 2026 - Target Batch - Vital
Hints
To view explanation, please take trial in the course.
NEET 2026 - Target Batch - Vital
The Adenosine deaminase deficiency results into:
| 1. | Digestive disorder | 2. | Addison's disease |
| 3. | Dysfunction of Immune system | 4. | Parkinson's disease |
Subtopic: Gene Therapy |
83%
From NCERT
NEET - 2021
To view explanation, please take trial in the course.
NEET 2026 - Target Batch - Vital
Hints
To view explanation, please take trial in the course.
NEET 2026 - Target Batch - Vital
Match the following columns and select the correct option.
| Column-I | Column-II | ||
| a. | Bt cotton | (i) | Gene therapy |
| b. | Adenosine deaminase deficiency | (ii) | Cellular defense |
| c. | RNAi | (iii) | Detection of HIV infection |
| d. | PCR | (iv) | Bacillus thuringiensis |
| a | b | c | d | |
| 1. | (iii) | (ii) | (i) | (iv) |
| 2. | (ii) | (iii) | (iv) | (i) |
| 3. | (i) | (ii) | (iii) | (iv) |
| 4. | (iv) | (i) | (ii) | (iii) |
Subtopic: Bt Crops | Interference RNA Tech | Gene Therapy | Molecular Diagnosis |
94%
From NCERT
NEET - 2020
To view explanation, please take trial in the course.
NEET 2026 - Target Batch - Vital
Hints
To view explanation, please take trial in the course.
NEET 2026 - Target Batch - Vital
© 2025 GoodEd Technologies Pvt. Ltd.